Financial Data and Key Metrics - Total operating expenses for Q3 2024 decreased by 24% to $27.3 million compared to $35.9 million in Q3 2023 [24] - Net loss for Q3 2024 was $25.2 million, or $0.89 per share, compared to a net loss of $33.9 million, or $1.52 per share, in Q3 2023 [24] - Cash, cash equivalents, and short-term investments stood at $84.8 million as of September 30, 2024, down from $145.3 million at the end of 2023 [25] - Estimated cash runway extends into Q3 2025, with an operational net cash burn of approximately $24 million projected for Q4 2024 [25] Business Line Data and Key Metrics - INO-3107, the lead product candidate, showed an 81% overall clinical response rate in the Phase 1/2 trial, with 28% of patients requiring no surgical intervention and 44% experiencing a reduction of at least 50% in surgeries [15] - INO-3112 is being evaluated in a proposed Phase 3 trial in combination with LOQTORZI for HPV16/18 positive oropharyngeal squamous cell carcinoma, with discussions ongoing with European regulators [8] - INO-5401 continues to be dosed in the GBM-001 trial for glioblastoma, with plans for a controlled Phase 2 trial [9] - INO-4201 is being developed as a heterologous boost to the Ebola vaccine Ervebo, with an upcoming FDA meeting to discuss Phase 2 trial design [10] Market Data and Key Metrics - The company is preparing for the potential commercialization of INO-3107, targeting a BLA submission by mid-2025 and aiming to be launch-ready by the end of 2025 [7][22] - Market research indicates strong potential for INO-3107, with feedback from payers confirming acceptability of pricing in line with rare disease standards [21] - The company is planning a lean and efficient commercial footprint, including field teams, to support the launch of INO-3107 [22] Company Strategy and Industry Competition - The company is focused on advancing INO-3107 towards commercialization while continuing to develop its broader pipeline, including INO-3112, INO-5401, and INO-4201 [5][8][9][10] - The company believes INO-3107 has a compelling product profile and could become the preferred treatment for RRP patients, supported by new immunology data [6][19] - The company is addressing a manufacturing issue related to the single-use component of its device, with progress being made towards resolution [7][35] Management Commentary on Operating Environment and Future Outlook - Management remains confident in the potential of INO-3107 to transform the treatment paradigm for RRP patients, supported by strong clinical and immunology data [6][19] - The company is focused on financial discipline, reducing operating expenses while advancing key programs [11] - Management anticipates announcing long-term durability data from the Phase 1/2 trial of INO-3107 by year-end [20] Other Important Information - The company has presented new immunology data at scientific conferences, highlighting the mechanism of action of INO-3107 and its potential to reduce or eliminate the need for surgeries in RRP patients [6][16][17] - The company is preparing for a confirmatory trial for INO-3107, which will be a placebo-controlled study with a two-to-one randomization and a longer follow-up period [43][50] Q&A Session Summary Question: Regulatory updates for INO-3107 outside the US - The company has met with UK and European regulators, who have advised that placebo-controlled data will be required for approval in those markets [28] - Discussions with Japan and China are ongoing, with interest in expanding into those regions [28] Question: Physician feedback on new immunology data - Physicians and key opinion leaders have been impressed with the immunology data, which supports the clinical efficacy of INO-3107 [29][31] Question: Steps to resolve manufacturing issues - The company is working closely with the manufacturer to address the issue with the single-use component of the device and is making good progress [35] Question: Competitive landscape for INO-3107 - The company believes INO-3107 has a differentiated product profile compared to competitors, with a focus on reducing the need for surgeries and a well-tolerated treatment regimen [38][39] Question: Confirmatory trial design for INO-3107 - The confirmatory trial will be a placebo-controlled study with a two-to-one randomization and a longer follow-up period to better characterize the clinical benefit of INO-3107 [43][50] Question: Redosing strategy for INO-3107 - The company plans to conduct redosing studies in commercial patients post-launch to evaluate the potential for maintaining long-term responses [62] Question: Commercial strategy for INO-3107 - The company plans to have MSLs and national account managers engage with health plans ahead of approval, with a focus on differentiating INO-3107 based on its clinical data [59]

XWELL, Inc. (NASDAQ:XWEL) Q3 2024 Earnings Conference Call November 14, 2024 5:00 PM ET Company Participants Suzanne Scrabis – Chief Financial Officer Ezra Ernst – Chief Executive Officer Conference Call Participants Operator Good day, and welcome to the XWELL, Inc. Third Quarter 2024 Results Conference Call. All participants will be in a listen-only mode. [Operator Instructions] I would now like to turn the conference over to Suzanne Scrabis, Chief Financial Officer. Please go ahead, ma’am. Suzanne Scrabis ...

Surf Air Mobility Inc. (NYSE:SRFM) Q3 2024 Earnings Conference Call November 14, 2024 5:00 PM ET Company Participants Deanna White - Chief Operating Officer and Interim Chief Executive Officer Oliver Reeves - Chief Financial Officer Sudhin Shahani - Co-Founder Conference Call Participants Ben Johnson - Piper Sandler Austin Moeller - Canaccord Genuity Operator Good afternoon, ladies and gentlemen. Thank you for standing by. My name is Brilla, and I will be your conference operator today. At this time, I woul ...

Ecopetrol S.A. (NYSE:EC) Q3 2024 Earnings Conference Call November 14, 2024 9:00 AM ET Company Participants Ricardo Roa - Chief Executive Officer Rafael Guzman - Acting Executive Vice President, Hydrocarbons David Riano - Executive Vice President, Transition Energy Camilo Barco - Chief Financial Officer Julián Lemos - Acting Vice President, Strategy & New Businesses Sandra RodrÃguez - Corporate Vice-President of Territorial Javier Cardenas - Chief Value Officer Conference Call Participants Katherine Ortiz - ...

Banco do Brasil S.A. (OTCPK:BDORY) Q3 2024 Earnings Conference Call November 14, 2024 8:00 AM ET Company Participants Janaina Storti - Manager -Investor Relations Tarciana Medeiros - Chief Executive Officer Felipe Prince - Vice President of Risk Geovanne Tobias - Chief Financial Officer Conference Call Participants Yuri Fernandes - JPMorgan Bernardo Guttmann - XP Renato Meloni - Autonomous Gustavo Schroden - Citi Eric Ito - Bradesco Bank Mario Pierry - Bank of America Carlos Gomez-Lopez - HSBC Pedro Leduc - ...

Financial Data and Key Metrics - Total revenue increased 23% to a quarterly record of nearly $39 million [11] - Adjusted EBITDA increased by 45% to a quarterly record of more than $12 million [11] - Net income attributable to common stockholders was $1.2 million or $0.05 per diluted share [11] - Gross profit expanded 32.9% year-over-year, producing a 58% gross margin in Q3 2024 compared to 54% in Q3 2023 [34] - Adjusted EBITDA margin was 31.5% compared to 26.7% for the same period last year [48] Business Line Data and Key Metrics - B2B channel lease funding approvals increased 33% during the third quarter to $77 million [11] - Signed store count increased nearly 250% from approximately 2,300 retail locations at the end of 2023 to approximately 7,800 locations [11] - B2C marketplace retail revenue increased from $780,000 for the quarter ended March 31, 2024 to $1.2 million for the quarter ended September 30, 2024 [14] - Total lease funding approvals were 33% higher at $77 million in Q3 of 2024, versus $57.9 million in Q3 of 2023 [42] Market Data and Key Metrics - The company has announced new partnerships with leading payment platforms, including Pay Tomorrow, Taris Finance, Versatile Credit, and Pay Possible [11] - The company has also announced retail partnerships with RANDYS Worldwide and Monro [11] - The company has a strong pipeline of potential payment and retail partners and expects to announce new partners in the coming months [12] Company Strategy and Industry Competition - The company is focused on pursuing proactive growth strategies within its B2C and B2B channels [11] - The company has invested in enhancing its internal underwriting, collections, and account servicing capabilities [11] - The company has filed patent infringement lawsuits against competitors Upbound and Katapult to protect its online LTO technology [20][21] - The company plans to expand its marketing spend to drive traffic and increase conversion on its B2C marketplace [15] Management Commentary on Operating Environment and Future Outlook - The company believes 2024 is shaping up to be a transformative year as its growth strategies take hold [9] - The company expects retail revenue to continue increasing over the coming quarters [15] - The company is optimistic about the direction of its business and the opportunities to create significant value for shareholders in 2025 and beyond [26] - The company plans to introduce AI-driven automation in collector servicing capabilities in 2025 [64] Other Important Information - The company has the opportunity to redeem 91% of its Series 2 Preferred Stock at a greater than 50% discount to its liquidation value of $44 million [22] - The redemption of the Series 2 Preferred Stock will be highly accretive to earnings and will contribute over $4 million to annual operating income [24] - The company has filed an S-1 registration statement with the SEC for a proposed rights offering to purchase up to 35 million units [54] Q&A Session Summary Question: Improvement in Payment Performance - The improvement in payment performance is driven by improved underwriting and fraud evaluation, quality of the customer, and servicing capabilities [62][63][64] Question: B2B Business Rollout Time - The rollout time for new locations typically takes six to nine months, with some variability due to seasonality and retailer adoption [66][67][68] Question: Revenue Mix Shift in Q4 - The fourth quarter typically sees a higher retail component, but many originations during the holiday season will not be fully represented until Q1 of the next year [69] Question: Gross Margin Benchmark - The company does not anticipate further significant reductions in bad debt but expects continued contribution from retail margin and top-line growth [71][72][73] Question: Retail Pipeline Acceleration - The acceleration in the retail pipeline is due to successful partnerships and the potential for more large deals in the future [81][82] Question: Debt Reduction and Net Income Utilization - The company plans to focus on deleveraging, growing the business, and lowering the cost of capital, with potential to transition to lower-cost debt capital as net income increases [84][85][86] Closing Remarks - The company looks forward to communicating its holiday season results on the next call [90]

Sensus Healthcare, Inc. (NASDAQ:SRTS) Q3 2024 Earnings Conference Call November 14, 2024 4:30 PM ET Company Participants Kim Golodetz - Alliance Advisors IR Joseph Sardano - Chairman and CEO Michael Sardano - President and General Counsel Javier Rampolla - CFO Conference Call Participants Jason Wittes - ROTH Anthony Vendetti - Maxim Ilya Zubkov - Freedom Broker Jade Montgomery - H.C. Wainwright Operator Good afternoon and welcome to the Sensus Healthcare Third Quarter 2024 Financial Results Conference Call. ...

Tivic Health Systems, Inc. (NASDAQ:TIVC) Q3 2024 Earnings Conference Call November 14, 2024 4:30 PM ET Company Participants Jennifer Ernst - Chief Executive Officer Operator Welcome to Tivic Health Systems' Third Quarter 2024 Financial Results and Operational Update Conference Call. This call has been pre-recorded and questions you have submitted in advance will be answered following the prepared remarks. This call is being webcast and the replay will be available on the IR section of the company's website ...

Motorsport Games Inc. (NASDAQ:MSGM) Q3 2024 Earnings Conference Call November 14, 2024 5:00 PM ET Company Participants Ben Rossiter-Turner - Investor Relations Stephen Hood - Chief Executive Officer Stanley Beckley - Chief Financial Officer Conference Call Participants Operator Thank you for standing by and welcome to Motorsport Games Inc. Third Quarter 2024 Earnings Call. [Operator Instructions]. As a reminder, today's conference is being recorded. I would like to turn the conference over to Ben Rossiter-T ...

T2 Biosystems, Inc. (NASDAQ:TTOO) Q3 2024 Earnings Conference Call November 14, 2024 4:30 PM ET Company Participants Trip Taylor - Investor Relations John Sperzel - Chairman & Chief Executive Officer John Sprague - Chief Financial Officer Conference Call Participants Yi Chen - H.C. Wainwright Operator Greetings. Welcome to the T2 Biosystems Incorporated Third Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal ...